Abstract

Increasing antibiotic resistance in pathogenic microorganisms has led to renewed interest in bacteriophage therapy in both humans and animals. A “Trojan Horse” approach utilizing liposome encapsulated phages may facilitate access to phagocytic cells infected with intracellular pathogens residing therein, e.g., to treat infections caused by Mycobacterium tuberculosis, Listeria, Salmonella, and Staphylococcus sp. Additionally, liposome encapsulated phages may adhere to and diffuse within mucosa harboring resistant bacteria which are challenges in treating respiratory and gastrointestinal infections. Orally delivered phages tend to have short residence times in the gastrointestinal tract due to clinical symptoms such as diarrhea; this may be addressed through mucoadhesion of liposomes. In the present study we have evaluated the use of a microfluidic based technique for the encapsulation of bacteriophages in liposomes having mean sizes between 100 and 300 nm. Encapsulation of two model phages was undertaken, an Escherichia coli T3 podovirus (size ~65 nm) and a myovirus Staphylococcus aureus phage K (capsid head ~80 nm and phage tail length ~200 nm). The yield of encapsulated T3 phages was 109 PFU/ml and for phage K was much lower at 105 PFU/ml. The encapsulation yield for E. coli T3 phages was affected by aggregation of T3 phages. S. aureus phage K was found to interact with the liposome lipid bilayer resulting in large numbers of phages bound to the outside of the formed liposomes instead of being trapped inside them. We were able to inactivate the liposome bound S. aureus K phages whilst retaining the activity of the encapsulated phages in order to estimate the yield of microfluidic encapsulation of large tailed phages. Previous published studies on phage encapsulation in liposomes may have overestimated the yield of encapsulated tailed phages. This overestimation may affect the efficacy of phage dose delivered at the site of infection. Externally bound phages would be inactivated in the stomach acid resulting in low doses of phages delivered at the site of infection further downstream in the gastrointestinal tract.

Highlights

  • The widespread inappropriate use of antibiotics in both humans and animals worldwide has led to an acceleration in the emergence and global spread of multidrug antibiotic resistant bacterial clones (Morgan et al, 2011)

  • The correspondence between growth curve CFU/ml and O.D. values gave us confidence that using O.D. values between 0.2 and 0.3 for both S. aureus and E. coli corresponded to ∼108 CFU/ml prior to phage addition

  • We have demonstrated the controlled microfluidic production of liposomes with a mean size in the range of 100–300 nm

Read more

Summary

Introduction

The widespread inappropriate use of antibiotics in both humans (clinical medicine) and animals (livestock industry) worldwide has led to an acceleration in the emergence and global spread of multidrug antibiotic resistant bacterial clones (Morgan et al, 2011). The problem of antibiotic resistance is a complex one requiring global coordination for antibiotic stewardship to preserve the efficacy of current treatments. In the period between 1940 and 1962, 20 new classes of antibiotics were introduced to the market; since 1962, there has been a discovery void with only two new classes reaching this stage (Coates et al, 2011). The speed of development of resistance has been faster than the rate of discovery (Kelly et al, 2016). The substantial public health threat from antibiotic resistance includes jeopardizing effectiveness of treatments in modern medicine from minor elective surgeries to cancer therapy

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call